Dr. Michael J Overman, MD
Claim this profileM D Anderson Cancer Center
Area of expertise
Colorectal Cancer
Michael J Overman, MD has run 4 trials for Colorectal Cancer. Some of their research focus areas include:
Colon Cancer
Michael J Overman, MD has run 4 trials for Colon Cancer. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
MD Anderson Cancer Center (MDACC)
Clinical Trials Michael J Overman, MD is currently running
PT886
for Stomach Cancer
This trial tests a new drug, PT886, on patients with advanced stomach, gastroesophageal, and pancreatic cancers. Researchers aim to see if it is safe and effective by observing its effects on the body and tumors.
Recruiting
1 award
Phase 1 & 2
Ramucirumab + Chemotherapy
for Small Bowel Cancer
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium, fluorouracil, and irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced or refractory small bowel cancers and may help patients live longer.
Recruiting
1 award
Phase 2
17 criteria
More about Michael J Overman, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Michael J Overman, MD has experience with
- Pembrolizumab
- Nivolumab
- Fluorouracil
- Leucovorin
- Synthetic Tumor-Associated Peptide Vaccine Therapy
- Fecal Microbiota Transplantation
Breakdown of trials Michael J Overman, MD has run
Colorectal Cancer
Colon Cancer
Solid Tumors
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael J Overman, MD specialize in?
Michael J Overman, MD focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are dMMR positive.
Is Michael J Overman, MD currently recruiting for clinical trials?
Yes, Michael J Overman, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Michael J Overman, MD has studied deeply?
Yes, Michael J Overman, MD has studied treatments such as Pembrolizumab, Nivolumab, Fluorouracil.
What is the best way to schedule an appointment with Michael J Overman, MD?
Apply for one of the trials that Michael J Overman, MD is conducting.
What is the office address of Michael J Overman, MD?
The office of Michael J Overman, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.